Changes in ratio of ineligible use of lamotrigine in Japan based on data from the relief system of the Pharmaceuticals and Medical Devices Agency
- 20 September 2020
- journal article
- letter
- Published by Wiley in Psychiatry and Clinical Neurosciences
- Vol. 75 (1) , 27-28
Abstract
No abstract availableKeywords
This publication has 4 references indexed in Scilit:
- A Standard Intervention Practice to Promote Appropriate Lamotrigine Therapy by PharmacistsBiological and Pharmaceutical Bulletin, 2018
- Severe drug eruptions due to lamotrigine in Japan based on data from the relief system of the Pharmaceuticals and Medical Devices AgencyAllergology International, 2017
- Safety and tolerability of emerging pharmacological treatments for bipolar disorderBipolar Disorders, 2005
- Lamotrigine and rash: scratching beneath the surface.The Journal of Clinical Psychiatry, 2002